Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-CAR-T2 Cells in r/r B-cell Leukemia/Lymphoma
NCT04605666Phase 2Completed
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- May 2020
- Primary completion
- Jun 2023
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19-CAR-T2 Cells in B cell acute lymphoblastic leukemia (B-ALL), B-cell non-Hodgkin lymphoma, sponsored by Nanfang Hospital, Southern Medical University. Started May 2020; status: completed.
02
Drugs
CD19-CAR-T2 Cells
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04605666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04605666.